- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
DUO-E Trial Data Support Durvalumab Combo as Potential Frontline Option in Advanced Endometrial Cancer
March 19th 2024, 4:04pm
Durvalumab plus carboplatin and paclitaxel, followed by maintenance durvalumab with or without olaparib, showed improved efficacy vs chemotherapy alone in endometrial cancer.
Lenvatinib Plus Pembrolizumab Displays Survival Benefit in Subgroups of Patients With Endometrial Cancer
March 19th 2024, 2:27pm
Lenvatinib plus pembrolizumab did not best chemotherapy in pMMR endometrial cancer, but did offer a survival benefit in some subgroups of patients.
Experts Share Top Highlights from the 2024 SGO Annual Meeting on Women’s Cancer
March 19th 2024, 1:00pm
From key sessions at the 2024 SGO Annual Meeting to updates in the field, gynecologic oncology experts share their key takeaways from the meeting.
Dr Marth on Frontline Lenvatinib Plus Pembrolizumab in Endometrial Cancer
March 19th 2024, 12:20am
Christian Marth, MD, PhD, discusses the LEAP-001 trial of lenvatinib plus pembrolizumab vs chemotherapy in advanced or recurrent endometrial cancer.
Dr Mirza on the Findings From Part 2 of the RUBY Trial in Endometrial Cancer
March 19th 2024, 12:05am
Mansoor Raza Mirza, MD, discusses findings from part 2 of the ENGOT-EN6-NSGO/GOG-3031/RUBY trial in primary advanced or recurrent endometrial cancer.
Mahtani Emphasizes Empowering Women in Oncology Through Sponsorship, Support Networks, and Self Care
March 18th 2024, 8:37pm
PER® Miami Breast Cancer Conference
Reshma Mahtani, DO, spotlights the challenges women in oncology may face throughout their careers and gives some advice to those just starting out.
McCann on the Intersection of Mentorship, Multidisciplinary Care, and Career Aspirations as a Woman in Oncology
March 18th 2024, 7:17pm
PER® Miami Breast Cancer Conference
Kelly E. McCann, MD, PhD, discusses her career journey and evolving career aspirations as a woman in oncology.
AI Models May Serve As Additional Genetic Counseling Resource in Gynecologic Oncology
March 18th 2024, 5:37pm
ChatGPT may provide comprehensive and correct answers to genetic counseling questions for patients with gynecologic cancers.
Disparities in Care Outcomes Persist Between Black and White Patients With Endometrioid Endometrial Carcinoma
March 18th 2024, 1:32am
Black patients with endometrioid endometrial carcinoma experienced an increased risk of death and lower enrollment in clinical trials vs White patients.
Dr Hayek on Laparoscopic vs Open Surgery in Advanced Ovarian Cancer
March 17th 2024, 9:50pm
Judy Hayek, MD, discusses outcomes with minimally invasive vs open interval complete gross resection in patients with advanced ovarian cancer.
Dr Randall on PROs With Pembrolizumab Plus Chemoradiotherapy in Cervical Cancer
March 17th 2024, 9:40pm
Leslie M. Randall, MD, MAS, discusses patient-reported outcomes from the ENGOT-cx11/GOG 3047/KEYNOTE-A18 trial in locally advanced cervical cancer.
Nab-Sirolimus Elicits Responses in Gynecologic/Peritoneal PEComa
March 17th 2024, 5:09pm
Patients with perivascular epithelioid sarcoma of gynecologic or peritoneal origin experienced durable responses when treated with nab-sirolimus.
Study Evaluates Synergistic Potential of Nab-Sirolimus Plus Letrozole in Advanced/Recurrent Endometrial Cancer
March 17th 2024, 5:00pm
The activity of nab-sirolimus plus letrozole is under study in patients with advanced or recurrent endometrioid endometrial cancer.
Dr Nasioudis on the Use of SLNB in Metastatic Vulvar Squamous Cell Carcinoma
March 16th 2024, 11:15pm
Dimitrios Nasioudis, MD, discusses outcomes of patients with metastatic vulvar squamous cell carcinoma who underwent sentinel lymph node biopsy.
Dr Corvigno on Chemotherapy-Related Clonal Hematopoiesis in Ovarian Cancer
March 16th 2024, 11:05pm
Sara Corvigno, MD, PhD, discusses the incidence of chemotherapy-related clonal hematopoiesis of indeterminate potential in patients with ovarian cancer.
Tislelizumab Plus Chemo Generates Responses in Locally Advanced Cervical Cancer
March 16th 2024, 9:26pm
Neoadjuvant tislelizumab in combination with chemotherapy was safe and produced responses in patients with locally advanced cervical cancer.
Mirvetuximab Soravtansine Associated With Improved HRQOL in FRα+ Ovarian Cancer
March 16th 2024, 8:41pm
Mirvetuximab soravtansine improved health-related quality of life in patients with FRα-positive, platinum-resistant ovarian cancer.
SBRT Shines in Early-Stage NSCLC and Demonstrates Efficacy With Immunotherapy
March 16th 2024, 8:00pm
Stereotactic ablative radiotherapy has shown clinical benefit in combination with immunotherapy in early-stage NSCLC, making it a viable treatment to consider.
Olaparib Plus Cediranib Falls Short in All-Comers With Platinum-Resistant or Refractory Ovarian Cancer
March 16th 2024, 7:40pm
Olaparib plus cediranib failed to improve PFS and OS vs chemotherapy in patients with platinum-resistant or -refractory epithelial ovarian cancer.
Dostarlimab Plus Chemo Demonstrates Survival Advantage in Advanced Endometrial Cancer
March 16th 2024, 6:43pm
Dostarlimab plus carboplatin/paclitaxel improved overall survival vs placebo plus chemotherapy in primary advanced or recurrent endometrial cancer.